Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215000, Jiangsu, China.
Department of Pathology, The First People's Hospital of Kunshan, Suzhou 215300, Jiangsu, China.
Urol Oncol. 2024 Aug;42(8):247.e1-247.e10. doi: 10.1016/j.urolonc.2024.03.018. Epub 2024 Apr 9.
Renal cell carcinoma (RCC) is a common malignant tumor with a high incidence in males and the elderly, and clear cell RCC (ccRCC) is the most common RCC subtype. ccRCC is highly metastatic with a poor prognosis. Therefore, it is crucial to obtain a detailed understanding of the molecular mechanism of ccRCC and to identify suitable biomarkers to realize early diagnosis and improve prognosis.
We analyzed data from the Cancer Genome Atlas, investigated the overall differential expression of CD276 in ccRCC, and evaluated the influence of CD276 on patient survival and prognosis. We also performed gene set enrichment analysis (GSEA) and pathway enrichment analysis and investigated cell infiltration and drug responsiveness to further assess the regulatory effect of CD276 on ccRCC. Furthermore, we verified CD276 expression in RCC cell lines and control cell lines.
The CD276 expression level in ccRCC samples was higher than that in corresponding samples adjacent to the tumors. Moreover, high CD276 expression levels were positively correlated with poor prognosis in patients with RCC. GSEA revealed that CD276 was significantly involved in immune-related pathways, and the level of CD276 expression was confirmed as associated with immune cell infiltration to some extent. Notably, some drugs were predicted to act on CD276, and this was confirmed by molecular docking. Furthermore, high levels of CD276 expression in RCC cell lines were verified.
CD276 expression was significantly increased in ccRCC tissues and cells and positively correlated with patient prognosis. CD276 is a potential prognostic biomarker of ccRCC. Overall, this study provides a potential therapeutic strategy for ccRCC.
肾细胞癌（RCC）是一种常见的恶性肿瘤，男性和老年人发病率较高，其中透明细胞 RCC（ccRCC）是最常见的 RCC 亚型。ccRCC 转移率高，预后差。因此，详细了解 ccRCC 的分子机制并识别合适的生物标志物以实现早期诊断和改善预后至关重要。
我们分析了癌症基因组图谱的数据，研究了 ccRCC 中 CD276 的整体差异表达，并评估了 CD276 对患者生存和预后的影响。我们还进行了基因集富集分析（GSEA）和通路富集分析，并研究了细胞浸润和药物反应性，以进一步评估 CD276 对 ccRCC 的调控作用。此外，我们验证了 RCC 细胞系和对照细胞系中 CD276 的表达。
ccRCC 样本中的 CD276 表达水平高于肿瘤相邻样本。此外，RCC 患者中 CD276 高表达水平与预后不良呈正相关。GSEA 显示 CD276 显著参与免疫相关途径，并且 CD276 的表达水平与免疫细胞浸润程度在一定程度上相关。值得注意的是，一些药物被预测作用于 CD276，分子对接也证实了这一点。此外，还验证了 RCC 细胞系中 CD276 的高表达。
CD276 在 ccRCC 组织和细胞中表达显著增加，并与患者预后呈正相关。CD276 是 ccRCC 的一个潜在预后生物标志物。总的来说，这项研究为 ccRCC 提供了一种潜在的治疗策略。
